Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

(b) and (c) On May 10, 2022, Jorge Gomez departed, effective immediately, from the role of Chief Financial Officer of Moderna, Inc. (the "Company"). In connection with Mr. Gomez's departure, he will be provided certain benefits under the Company's Amended and Restated Executive Severance Plan, comprising (i) 12 months' salary, totaling $700,000, and (ii) COBRA coverage for 12 months. Mr. Gomez will forfeit his signing bonus, eligibility for relocation reimbursements, bonus eligibility and his eligibility for new hire equity awards that were disclosed by the Company in a Current Report on Form 8-K on April 11, 2022. Mr. Gomez's departure follows the public disclosure on May 10, 2022 by Mr. Gomez's former employer, Dentsply Sirona Inc., of an ongoing internal investigation into certain matters, including financial reporting.

David Meline, the Company's recently retired Chief Financial Officer, will continue as Chief Financial Officer, effective May 11, 2022. Mr. Meline will continue to receive the benefits for which he was eligible while employed as Chief Financial Officer, which include an annual salary of $700,000, with an annual incentive target of 90% of his annual base salary, based upon achievement of certain individual performance goals and/or company performance goals established by the Company. Achievement of the goals will be determined in the sole discretion of the Compensation and Talent Committee of the Board of Directors (the "Compensation Committee"). In addition, in connection with Mr. Meline's continued service as Chief Financial Officer, the Compensation Committee has agreed that Mr. Meline will continue to remain eligible for the full vesting of his 2022 annual stock option and restricted stock unit equity awards that were otherwise scheduled for forfeiture upon his retirement as an employee in July 2022, and Mr. Meline will also be granted 12 months from the last date of any service relationship with the Company to exercise any vested but unexercised stock options that he holds as of that date. Mr. Meline joined the Company as Chief Financial Officer in June 2020. Prior to joining the Company, Mr. Meline, 64, served as Executive Vice President and Chief Financial Officer of Amgen Inc. from 2014 to 2019. He previously held senior finance roles with 3M Company and General Motors.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses